By

Luke Timmerman

10
Feb
2022

Biotech’s Future off The Beaten Path

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.
2
Feb
2022

TR’s 7th Anniversary: Thank You

Timmerman Report is 7 years old today. On Feb. 2, 2015, I rode my bike to the office on a wet Seattle morning and turned on the lights. I thought there was a need for clear, probing, contextual biotech journalism. It was a leap of faith, like any entrepreneurial venture. I couldn’t have predicted 90 percent of what came next....
Read More
1
Feb
2022

Targeting Integrins With Small Molecules: Praveen Tipirneni on The Long Run

Today’s guest on The Long Run is Praveen Tipirneni. Praveen is the CEO of Waltham, Mass.-based Morphic Therapeutic. Morphic Therapeutic is developing oral small molecule drugs aimed at integrin targets. There’s some fascinating biology and computational technology underpinning this work, which I discussed a couple years ago on The Long Run with Morphic scientific founder Tim Springer. Just to review...
Read More
27
Jan
2022

A Small Step on Drug Pricing

Mark Cuban, the billionaire-turned-reality TV star, made news this week with the Mark Cuban Cost Plus Drug Company. Cuban has been saying for a while that he wants to stick it to the man. The biopharma man. “I could make a fortune from this,” Cuban told Texas Monthly in September. “But I won’t. I’ve got enough money. I’d rather f—...
Read More
20
Jan
2022

Reflecting on MLK and Science in Society

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.
13
Jan
2022

The Biogen Debacle Continues

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.
9
Dec
2021

A Missed Opportunity for Grownups

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.
6
Dec
2021

Targeted Small Molecule Protein Degraders: Nello Mainolfi on The Long Run

Today’s guest on The Long Run is Nello Mainolfi. Nello is the president and CEO of Cambridge, Mass.-based Kymera Therapeutics. Kymera is working on targeted protein degraders. These are orally available small molecule compounds. Many in biopharma are excited about them because they have a clever design that allows them to go after targets that have previously been out of...
Read More
2
Dec
2021

The Variant on the Move

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.